

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 81714

**Title:** Budd-Chiari Syndrome in Myeloproliferative Neoplasms: a review

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03656606

**Position:** Peer Reviewer

**Academic degree:** Doctor, MD, PhD

**Professional title:** Chief Doctor, Director, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Romania

**Manuscript submission date:** 2022-11-20

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-25 01:58

**Reviewer performed review:** 2022-11-28 12:16

**Review time:** 3 Days and 10 Hours

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

This review article, regarding Budd-Chiari syndrome (BCS) in MPNs, is of high quality. The author focuses on epidemiology, pathogenesis, histopathology, risk factors, classification, clinical presentation, diagnosis, and management of BCS in MPNs. Readers of World Journal of Gastroenterology should be interested in this article.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 81714

**Title:** Budd-Chiari Syndrome in Myeloproliferative Neoplasms: a review

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 00003629

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Emeritus Professor

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** Romania

**Manuscript submission date:** 2022-11-20

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-06 15:29

**Reviewer performed review:** 2022-12-20 09:42

**Review time:** 13 Days and 18 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements	Conflicts-of-Interest: [ ] Yes [Y] No
------------	---------------------------------------

## SPECIFIC COMMENTS TO AUTHORS

Major Comments: 1. (Page 10, Line 29): Please replace “veno-occlusive disease” by “porto-sinusoidal vascular disorder” (J Hepatol 2022;77:1124-1135). 2. (Page 11, Lines 21-22): “whereas obstruction of the hepatic vena cava was more common in males”: Please explain whether you refer to inferior vena cava or to another vessel. The term “hepatic vena cava” is confusing. 3. (Page 11, Lines 31): Authors must be more precise for what they mean by “hepatic outflow obstruction” as contrasted to “hepatic vein obstruction”. 4. (Page 15, Line 28): Please clarify what do you mean by “hepatic venous obstruction”: “Inferior vena cava obstruction” or “hepatorenal syndrome type I or II”? 5. (Page 19, Lines 6, 7 & elsewhere): Please, replace the word “Anamnesis” with “Medical History”. 6. (Page 23, Line 1): Please consider shortening Part 9 to ~5 pages. 7. (Page 24, Line 12): Beside vein re-occlusion following angioplasty, authors should also report the expected mortality following open abdominal surgery in a BCS patient. 8. (Page 26, Lines 1-2): Please, discuss the advisability of liver transplantation in BCS due to MPNs, considering the expected patients' survival of each one MPN (Consider also: Medicina DOI: 10.3390/medicina57080821). 9. (Page 28, Line 6): Please update use of DOACs in BCS See Ref. Clin Gastroenterol Hepatol. DOI: 10.1016/j.cgh.2022.04.024. 10. (Page 30, Line 25): The content of Part 10 has already been dealt with in part elsewhere in the text. If there is other important information not already mentioned, authors can incorporate it in Part 7 or 8 of this article. 11. (Page 33, Line 1): Please, reduce the number of references by 25% (in total, less than 125). Minor Comments: 1. (Page 5, Lines 6-8): Please modify the sentence. It is the 3rd time you repeat it. 2. (Page 6, Line 7): Please mention directly “hepatocellular carcinoma”, since it is the main underlying primary liver malignancy causing PVT. 3. (Page 6, Line 26): ...“in these individual parameters”... 4. (Page 12, Line



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

13): Please explain abbreviations when first written. Generally speaking, abbreviations make reading more difficult. Avoid them wherever possible. 5. (Page 13, Line 16): Please give another abbreviation for “polycythemia vera”. PV is confused with “portal vein”. 6. (Page 25, Lines 14-77): “With reduction of re-intervention, tripling the shunt patency and improving prognosis of patients following TIPS, the development of stents coated with polytetrafluoroethylene (PTFE) in BCS patients becomes much more significant.”: Please rephrase the sentence in a more understandable way. 7. (Page 30, Line 4): Please omit the phrase “that may arise from the vena cava obstruction caused by the disease”. 8. (Page 31, Line 2): ...non-cancerous PVT.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 81714

**Title:** Budd-Chiari Syndrome in Myeloproliferative Neoplasms: a review

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02904354

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Academic Editor, Associate Chief Physician, Associate Professor,  
Deputy Director

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Romania

**Manuscript submission date:** 2022-11-20

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-21 04:14

**Reviewer performed review:** 2022-12-30 13:41

**Review time:** 9 Days and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The overall logic and structure of this article are confusing, and the authors need to carefully check the article and make serious modifications. The "Abstract" section is similar to the "Introduction" section. The authors need to rewrite the "Abstract" section to ensure that the content is suitable for publication. The abbreviations of proper nouns appearing in the article can only be marked with brackets when they first appear in the article. PVT is not the focus of this article, so the part "BRIEF OVERVIEW OF PVT" should be deleted. In the section "MANAGEMENT OF BCS IN MPNS", there is a grammatical error in the sentence "The primary risk associated with stenting is that exclusion of the vessel that the stem is placed in is common". Please check and modify it. In the "MANAGEMENT OF BCS IN MPNS" section (Line 9-10 on page 25), it is more reasonable for the authors to change "liver cell" to "hepatocyte". In addition, cell death includes cell apoptosis and cell necrosis. Therefore, "Necrosis" and "cell death" should not be connected by "and". In the "MANAGEMENT OF BCS IN MPNS" section, the arrangement of the content is confusing. In this section, the authors mentioned many effective treatment methods, but there are only three subheadings "Long term

antithrombotic treatment", "Cytoconductive therapy" and "Orthotopic Living Transportation", which are unreasonable. The authors should reintegrate and rearrange this part of the content. Some sentences are inappropriate in review articles (Line 15-19 on page 30). Please revise them. In China, the number of BCS patients caused by MPN is very small, which should be discussed in the article (PMID: 23447059). The value of CALR in the diagnosis of MPN in BCS patients should be discussed in this article (PMID: 29803161). Molecular-driven diagnosis and long-term treatment of patients with BCS resulting from MPNs patients should be discussed in this article (PMID: 26333846). There are many details in the article that need to be carefully reviewed and revised by the authors. Authors should be careful to check all use of the abbreviation "Myeloproliferative neoplasms" in the article to ensure that it is used accurately. The authors are requested to recheck all the writing of "JAK2V617F" in the article to ensure that the full article remains uniform. In the "CLINICAL PRESENTATION OF BCS" section (Line 11 on page 16), the authors should change "Eastern" to "eastern". In the "DIFFERENTIAL DIAGNOSIS, PROGNOSIS, COMPLETIONS OF BCS IN MPNS" section (Line 8 on page 31), the authors should change "doppler" to "Doppler". The authors should carefully check the citation format of each reference again to ensure that it is correct. The authors did not mark the corresponding position of "Table 1" and "Table 2" in the article. The format of subtitles in each part of the article should be consistent. The full names of "LFT", "ALT", and "AST" (Line 14 on page 20) are not introduced in this article.